|

SAR445877 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Sanofi1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer2
  • ICI-refractory1
  • Solid Tumor1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1

Newark, Delaware1 trial

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Christiana Care Health System- Site Number : 8400011

Phase 1/2

Houston, Texas1 trial

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.